Company news
Supernus Pharmaceuticals, Inc. news in 2021
Supernus Pharmaceuticals, Inc.'s news releases, calls and decks from 2021, newest first.
Supernus Pharmaceuticals Targeted in Ransomware Incident
November 23, 2021
Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals
November 23, 2021
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer
November 22, 2021
Supernus to Participate in Annual Piper Sandler Healthcare Conference
November 17, 2021
Supernus to Participate in Upcoming November Investor Conferences
November 9, 2021
Supernus Announces Third Quarter 2021 Financial Results
November 2, 2021
Supernus to Announce Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021
October 26, 2021
Holly Robinson Peete Partners with Supernus to Raise Awareness During ADHD Awareness Month
October 19, 2021
Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio
October 10, 2021
Supernus to Participate in Upcoming September Investor Conferences
September 1, 2021
Supernus Announces Qelbree™ sNDA for Adult Indication Accepted for Review by FDA
September 1, 2021
Supernus Announces Second Quarter 2021 Financial Results
August 3, 2021
Supernus to Host Second Quarter 2021 Financial Results Conference Call
July 21, 2021
Supernus to Present at Jefferies Virtual Healthcare Conference
May 24, 2021
Qelbree™ (viloxazine extended-release capsules), a New Non-Controlled Substance, Now Available for the Treatment of ADHD in Pediatric Patients 6-17 Years of Age
May 23, 2021
Supernus Announces First Quarter 2021 Financial Results
May 4, 2021
Supernus Announces Paragraph IV ANDA Filing for XADAGO®
May 3, 2021
Supernus to Host First Quarter 2021 Financial Results Conference Call
April 26, 2021
Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD
April 1, 2021
Supernus to Present at Cowen Healthcare Conference
February 25, 2021
Supernus Announces Fourth Quarter and Full Year 2020 Financial Results
February 24, 2021
Supernus to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call
February 22, 2021
Supernus Receives FDA Notice Assigning Early April 2021 PDUFA Date for SPN-812 NDA
February 21, 2021
Supernus Resubmits New Drug Application for SPN-812 for the Treatment of ADHD in Pediatric Patients
February 7, 2021
Supernus to Present at J.P. Morgan 39th Annual Healthcare Conference
January 5, 2021
Calls in 2021
- Supernus Pharmaceuticals (NASDAQ:SUPN) Q3 2021 Earnings Call
Nov 3, 2021
Transcript - Supernus Pharmaceuticals (NASDAQ:SUPN) Q2 2021 Earnings Call
Aug 4, 2021
Transcript - Supernus Pharmaceuticals (NASDAQ:SUPN) Q1 2021 Earnings Call
May 5, 2021
Transcript - Supernus Pharmaceuticals (NASDAQ:SUPN) Q4 2020 Earnings Call
Feb 25, 2021
Transcript
Decks in 2021
- Merger or Acquisition (October 2021)
Merger or acquisition · 19 slides · Oct 12, 2021